Evolus Inc., a performance beauty company, has announced a partnership with Symatese to distribute Nuceiva® (botulinum toxin type A) in France. This move is part of Evolus's geographic expansion strategy, aiming to deliver its aesthetic solutions to the French market. Nuceiva®, known as Jeuveau® in the United States, has been the fastest-growing neurotoxin there for four consecutive years. The product is approved for improving the appearance of severe glabellar lines in adults below 65. The collaboration with Symatese, a well-established French firm in the aesthetics industry, will facilitate direct order and delivery of Nuceiva® to healthcare professionals in France, marking a significant step in Evolus's global growth strategy.